Cosmo valuation report update "Back to the roots"

Sunday, August 6, 2023 @ 12:00 am

H1 2023 results driven by strong GI Genius, Lialda, and Contract manufacturing growth. Cosmo will repay EUR 175 mn convertible bonds in November 2023 with cash. FY 2023 guidance was maintained despite USD headwind signaling a strong H2 boosted by strong upfront and sales milestones for Winlevi with several new agreements underway.

Key catalysts include:

CB-01-33 start POC trial in bile acid diarrhea (H2 2023)
Winlevi licensing agreements (during 2023)
Winlevi filing for EU approval (H2 2023)

To the full Cosmo Valuation Report

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Solvias opens center for biologics, cell & gene therapy in North Carolina

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today the opening of its cutting-edge Center of Excellence for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina. The new facility expands Solvias’ global network of centers and reinforces its commitment to advancing transformative therapies for cancer and
January 27, 2025

Altamira Therapeutics: Collaboration on radiopharmaceutical targeting strategies

Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have option to negotiate licensing and supply agreement
January 22, 2025

LubioScience partners with Cayman Chemical to expand research tools for Swiss scientists

LubioScience GmbH, Switzerland’s largest R&D reagent platform, got into a new partnership with Cayman Chemical, a global leader in biochemicals, assay kits, and lipid research tools. This partnership brings Cayman's innovative products and expert services to the Swiss research community, supporting advancements in cancer, neuroscience, metabolism, drug discovery, and more.
January 22, 2025

Ymmunobio and PSI win Innosuisse grant for treatment and diagnostic of solid tumors with radio pharmaceutical

Ymmunobio and the Paul Scherrer Institute win Innosuisse innovation grant to develop a radio pharmaceutical with YB’s proprietary YB-800
January 20, 2025

abc biopply & Preclina: Collaboration to improve predictiveness of preclinical studies

abc biopply AG, a pioneer innovator of humanized multi-organoid disease models, and Preclina Inc., a preclinical contract research organization specializing in immune related disorders and humanized animal models, have announced a strategic collaboration. The partnership between the two companies will provide customers with end-to-end project planning on humanized preclinical models from early in
January 18, 2025